Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ARNA 6.21 -0.09 (-1.43%)
price chart
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): TV Ads For Belviq Launched
Dallas, Texas 04/17/2014 (ustradevoice) - One of the main reasons, analysts and pundits say, why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has not had success with its FDA-approved weight management drug known as Belviq, is lack of awareness.
Small Cap Recent Insider Selling: Arena Pharmaceuticals (NASDAQ:ARNA ...  Tech News
Biotech recent insider selling: Arena Pharmaceuticals (NASDAQ:ARNA ...  Gaining Green
Related articles »  
What Arena's Belviq Television Ad Campaign Means For The Stock
The weight loss drug Belviq from Arena Pharmaceuticals (ARNA) is now being promoted on television with a national advertising campaign.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The Future Is Encouraging
That being the case, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) seems to have come to the realization that unless it takes proactive steps to expand the market share of its anti-obesity drug Belviq, it might as well miss out on a great opportunity.
Active Movers � LeapFrog Enterprises, Inc. (NYSE:LF), Arena Pharmaceuticals ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), is a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, ...
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL ...
Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at: On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to close the day at $6.38. The stock recorded a ...
Related articles »  
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Expecting Sales to hit $150M this ...
Dallas, Texas 03/31/2014 (ustradevoice) - Biopharmaceutical Company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), expects majority of its revenue for the year to come from its flagship drug, Belviq.
Arena Pharmaceuticals, Inc. (ARNA) news: Direct-To-Consumer Television ...
Arena (ARNA) and its marketing partner Eisai (OTCPK:ESALY) recently announced a major new stage in commercialization strategy and promotional mix that I believe could be the tipping point for a significant upward inflection in BELVIQ sales.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Plans For A Bright Tomorrow
Dallas, Texas 03/19/2014 (ustradevoice) - Arena Pharmaceuticals Inc. (NASDAQ:ARNA) has been in the news lately for introducing the new drug BELVIQ.
To Play Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Patience Is Needed  WallStreetPR
Related articles »  
Arena - Belviq Sales Up Modestly Heading Into Television Ads
It is certainly an interesting time to be an investor in Arena Pharmaceuticals (ARNA). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way.
Related articles »  
Arena Pharmaceuticals Reports Eisai's Launch of National Television ...
SAN DIEGO, April 14, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ � (lorcaserin HCl), an FDA-approved prescription treatment for ...
Eisai Launches BELVIQ Marketing Campaign (ARNA) (subscription)
Related articles »